Nicotine Addiction-Pipeline Review, H1 2016

Nicotine Addiction-Pipeline Review, H1 2016


  • Products Id :- GMDHC7741IDB
  • |
  • Pages: 60
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Nicotine Addiction-Pipeline Review, H1 2016', provides an overview of the Nicotine Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nicotine Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nicotine Addiction and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Nicotine Addiction

The report reviews pipeline therapeutics for Nicotine Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Nicotine Addiction therapeutics and enlists all their major and minor projects

The report assesses Nicotine Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Nicotine Addiction

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Nicotine Addiction

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Nicotine Addiction pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Nicotine Addiction Overview 7

Therapeutics Development 8

Pipeline Products for Nicotine Addiction-Overview 8

Pipeline Products for Nicotine Addiction-Comparative Analysis 9

Nicotine Addiction-Therapeutics under Development by Companies 10

Nicotine Addiction-Therapeutics under Investigation by Universities/Institutes 11

Nicotine Addiction-Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Nicotine Addiction-Products under Development by Companies 14

Nicotine Addiction-Products under Investigation by Universities/Institutes 15

Nicotine Addiction-Companies Involved in Therapeutics Development 16

Addex Therapeutics Ltd 16

Astraea Therapeutics, LLC 17

Cerecor Inc. 18

Embera NeuroTherapeutics, Inc. 19

Hager Biosciences, LLC 20

Heptares Therapeutics Limited 21

Omeros Corporation 22

RTI International 23

Nicotine Addiction-Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Combination Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 31

Drug Profiles 33

(metyrapone + oxazepam)-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

ADX-71441-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

AT-1001-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

CERC-501-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Drugs to Inhibit FAAH for CNS Disorders-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

EORA-101-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

OMS-405-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

OMS-527-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Small Molecule to Antagonize Alpha-4 Beta-2 Nicotinic Acetylcholine Receptor for CNS Disorders-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Small Molecules to Antagonize CRF-R1 and OREXIN-1 for Nicotine Addiction-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Vaccine for Nicotine Addiction-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Vaccine for Nicotine Addiction-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Nicotine Addiction-Recent Pipeline Updates 49

Nicotine Addiction-Dormant Projects 54

Nicotine Addiction-Discontinued Products 55

Nicotine Addiction-Product Development Milestones 56

Featured News & Press Releases 56

Dec 11, 2015: Publication Reports Human Brain Penetration and Target Engagement of Cerecor's Oral Kappa Opioid Receptor Antagonist, CERC-501 56

Jul 10, 2014: Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction 56

Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction 57

May 05, 2011: Omeros Announces Expansion Of Potential Indications For PDE7 Inhibitors 57

Appendix 59

Methodology 59

Coverage 59

Secondary Research 59

Primary Research 59

Expert Panel Validation 59

Contact Us 59

Disclaimer 60

List of Figures

Number of Products under Development for Nicotine Addiction, H1 2016 8

Number of Products under Development for Nicotine Addiction-Comparative Analysis, H1 2016 9

Number of Products under Development by Companies, H1 2016 10

Number of Products under Investigation by Universities/Institutes, H1 2016 11

Comparative Analysis by Early Stage Products, H1 2016 13

Assessment by Monotherapy Products, H1 2016 24

Number of Products by Top 10 Targets, H1 2016 26

Number of Products by Stage and Top 10 Targets, H1 2016 26

Number of Products by Top 10 Mechanism of Actions, H1 2016 28

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 28

Number of Products by Stage and Routes of Administration, H1 2016 30

Number of Products by Molecule Types, H1 2016 31

Number of Products by Stage and Molecule Types, H1 2016 31

List of Tables

Number of Products under Development for Nicotine Addiction, H1 2016 8

Number of Products under Development for Nicotine Addiction-Comparative Analysis, H1 2016 9

Number of Products under Development by Companies, H1 2016 10

Number of Products under Investigation by Universities/Institutes, H1 2016 11

Comparative Analysis by Clinical Stage Development, H1 2016 12

Comparative Analysis by Early Stage Development, H1 2016 13

Products under Development by Companies, H1 2016 14

Products under Investigation by Universities/Institutes, H1 2016 15

Nicotine Addiction-Pipeline by Addex Therapeutics Ltd, H1 2016 16

Nicotine Addiction-Pipeline by Astraea Therapeutics, LLC, H1 2016 17

Nicotine Addiction-Pipeline by Cerecor Inc., H1 2016 18

Nicotine Addiction-Pipeline by Embera NeuroTherapeutics, Inc., H1 2016 19

Nicotine Addiction-Pipeline by Hager Biosciences, LLC, H1 2016 20

Nicotine Addiction-Pipeline by Heptares Therapeutics Limited, H1 2016 21

Nicotine Addiction-Pipeline by Omeros Corporation, H1 2016 22

Nicotine Addiction-Pipeline by RTI International, H1 2016 23

Assessment by Monotherapy Products, H1 2016 24

Assessment by Combination Products, H1 2016 25

Number of Products by Stage and Target, H1 2016 27

Number of Products by Stage and Mechanism of Action, H1 2016 29

Number of Products by Stage and Route of Administration, H1 2016 30

Number of Products by Stage and Molecule Type, H1 2016 32

Nicotine Addiction Therapeutics-Recent Pipeline Updates, H1 2016 49

Nicotine Addiction-Dormant Projects, H1 2016 54

Nicotine Addiction-Discontinued Products, H1 2016 55

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Addex Therapeutics Ltd

Astraea Therapeutics, LLC

Cerecor Inc.

Embera NeuroTherapeutics, Inc.

Hager Biosciences, LLC

Heptares Therapeutics Limited

Omeros Corporation

RTI International

Nicotine Addiction Therapeutic Products under Development, Key Players in Nicotine Addiction Therapeutics, Nicotine Addiction Pipeline Overview, Nicotine Addiction Pipeline, Nicotine Addiction Pipeline Assessment

select a license

Single User License
USD 2000 INR 128160
Site License
USD 4000 INR 256320
Corporate User License
USD 6000 INR 384480

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com